Cold-cough

Commercial

Portfolio-7447-for-WEB

NCE Pipeline

Discovery-7447-for-WEB

Research

Latest Annual Report

Vernalis-AR2013-CoverApr 01, 2014

2013 Results Download our latest report...        


Archive

Latest Webcast

ceoApril 01, 2014

Our latest webcast is available to view here...


Archive

Share Price

Share price:  47.75p
Change:  -0.25 (-0.52%)
As at:  05 March 2015 09:31:47
Volume:  3,698
LSE ID:  VER

Share price details

Latest News

Vernalis licenses proprietary adenosine receptor antagonist technology, including lead compound V81444, for, development and commercialisation

Vernalis plc today announces that it has licensed exclusive, worldwide rights in its adenosine receptor antagonist programme, including the lead drug candidate, V81444, for use in all therapeutic applications to a well-funded, US-based biotechnology company...

Read more...

At a glance

More information on Vernalis and it's pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form